Ilumya is a biologic that was approved for the treatment of psoriasis in 2018.
What is Ilumya?
Ilumya (also known by its generic name tildrakizumab-asmn) is a biologic medication that was approved by the FDA in March 2018 for the treatment of moderate-to-severe plaque psoriasis in adults.
Ilumya is given by injection under the skin at weeks 0, 4, and every 12 weeks thereafter.
Last updated on 3/24/25 by the National Psoriasis Foundation.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.